Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 233 publications
Intratumoral dose heterogeneity promotes adaptive anti-tumor immunity and predicts clinical response to radiopharmaceutical therapy.
Journal: bioRxiv : the preprint server for biology
Published: August 01, 2026
Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis.
Journal: Radiology. Imaging cancer
Published: June 18, 2026
Re: [177Lu]-PSMA-617-PSMA-617 in Oligometastatic Hormone Sensitive Prostate Cancer (BULLSEYE): An Open-label, Randomised, Phase 2 Study.
Journal: European urology
Published: June 12, 2026
The Research Post.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 01, 2026
The Role of FAPI PET/CT in the Assessment of Inflammatory Diseases.
Journal: Seminars in nuclear medicine
Published: March 25, 2026
Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 23, 2026
Reply to: Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 18, 2026
Clinical Trial Protocol for LPS-Boost: Intensified [177Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 08, 2026
The Patient Post.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 11, 2026
PSMA PET Imaging for Prostate Cancer Recurrence After Minimally Invasive Focal Therapy: A Single-Center Retrospective Study.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 12, 2026
131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 27, 2025
Last Updated: 09/26/2026